Estrella Immunopharma, Inc. Annual Net Cash Provided by (Used in) Financing Activities in USD from 2021 to 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Estrella Immunopharma, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2021 to 2024.
  • Estrella Immunopharma, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending September 30, 2024 was -$150K, a 101% decline year-over-year.
  • Estrella Immunopharma, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $12.8M.
  • Estrella Immunopharma, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was -$35.6M, a 177% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $12.8M Jul 1, 2023 Jun 30, 2024 10-K 2024-09-27
2022 -$35.6M -$81.5M -177% Jan 1, 2022 Dec 31, 2022 10-K 2023-03-14
2021 $46M Jan 6, 2021 Dec 31, 2021 10-K 2023-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.